JY
NMRA icon

Jeff Yass’s Neumora Therapeutics NMRA Stock Holding History

Jeff Yass’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$152K Sell
89,500
-70,000
-44% -$133K ﹤0.01% 12197
2026
Q1 		$311K Buy
159,500
+98,400
+161% +$255K ﹤0.01% 10784
2025
Q4 		$109K Buy
61,100
+24,600
+67% +$53.9K ﹤0.01% 11406
2025
Q3 		$66.4K Buy
36,500
+24,200
+197% +$39.1K ﹤0.01% 11763
2025
Q2 		$8.98K Sell
12,300
-15,500
-56% -$11.7K ﹤0.01% 12410
2025
Q1 		$27.8K Sell
27,800
-410,000
-94% -$702K ﹤0.01% 12032
2024
Q4 		$4.64M Buy
437,800
+400,900
+1,086% +$4.8M ﹤0.01% 3713
2024
Q3 		$487K Buy
+36,900
New +$430K ﹤0.01% 8524
2024
Q1 		– Sell
-14,200
Closed -$242K – 12952
2023
Q4 		$242K Buy
+14,200
New +$174K ﹤0.01% 10292

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jeff Yass's NMRA Position: Q2 2026 in Review

Jeff Yass reduced its Neumora Therapeutics (NMRA) stake by 70% in Q2 2026, selling an estimated $1.65M and leaving 374,014 shares worth $636K. The position accounts for ﹤0.01% of the portfolio, ranked #9348.

Jeff Yass first reported a position in NMRA in Q3 2023 and has held it in 12 quarters since. The position peaked at $2.42M in Q1 2026. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Jeff Yass held 374,014 shares of Neumora Therapeutics worth $636K as of Q2 2026.
  • Jeff Yass sold 866,227 Neumora Therapeutics shares in Q2 2026, an estimated $1.65M.
  • Neumora Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #9348 holding.
  • Jeff Yass first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Jeff Yass's Neumora Therapeutics position peaked at $2.42M in Q1 2026.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.